Ann: Half Yearly Report and Accounts, page-2

At least mentioned in the HY-Report. Time will tell if both vaxx are any good or not. The data suggest a big YES, the results to date of trying to get a deal on the other hand suggest a big NO.

But as yesterday's CHM anns proved, anything, even the most "impossible", can happen at any time.


B-CELL IMMUNOTHERAPY PROGRAMS
The HER-Vaxx cancer immunotherapy program has now been completed, with final results presented
at the San Antonio Breast Cancer Symposium and the European Society of Medical Oncology Congress.
Additionally, the B-cell immunotherapy PD1-Vaxx will be part of an upcoming Phase 2 Investigator
Sponsored Trial (IST), known as Neo-POLEM, which is expected to begin in the first half of 2025.
This study will recruit approximately forty patients with colorectal cancer in Australia and the UK, with
PD1-Vaxx being administered in a neoadjuvant setting prior to surgery. As previously indicated, the B-cell
immunotherapy programs have been deprioritized to allow the company to focus on the azer-cel and
oncolytic virotherapy programs. Imugene’s management is actively exploring out-licensing opportunities
for these assets.